| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
JNK1; JNK2; NF-κB
Isovitexin targets multiple signaling pathways involved in inflammation, oxidative stress, and cancer. It acts as a JNK1/2 inhibitor, suppressing JNK-mediated signaling. It blocks the activation of NF-κB, a key transcription factor in inflammation and cancer. Its antioxidant activity involves free radical scavenging and protection against oxidative damage. Its anticancer effects are mediated through inhibition of cell proliferation and induction of apoptosis. Its neuroprotective effects suggest protection of neuronal cells. |
|---|---|
| ln Vitro |
In vitro, Isovitexin has demonstrated antioxidant and anti-inflammatory activities. It acts as a JNK1/2 inhibitor and blocks the activation of NF-κB. It has anticancer effects. It has anti-Alzheimer's disease (AD) effects. It has neuroprotective effects. These activities confirm its potential for research on inflammation, oxidative stress, cancer, and neurodegenerative diseases.
|
| ln Vivo |
In vivo, Isovitexin has been studied for its anti-inflammatory, antioxidant, and neuroprotective effects. Its JNK1/2 inhibition and NF-κB blockade suggest potential for treating inflammatory and neurodegenerative diseases. However, detailed in vivo efficacy and safety data are described in the primary literature. The compound is primarily used in research applications. Further studies are needed to fully characterize its in vivo therapeutic potential. The compound is intended for research use only.
|
| Enzyme Assay |
For in vitro biochemical assays, Isovitexin is evaluated for its enzyme inhibitory and antioxidant activities. JNK1/2 inhibition is measured using kinase assays with recombinant JNK proteins and specific substrates. NF-κB activation is assessed using cell-free transcription assays or by measuring NF-κB DNA binding. Antioxidant activity is measured using DPPH, ABTS, or FRAP assays. Anti-inflammatory activity is assessed by measuring inhibition of inflammatory mediators. These cell-free and cell-based assays help characterize the compound's multiple biological activities.
|
| Cell Assay |
In vitro cellular assays for Isovitexin are performed using various cell types including immune cells, cancer cells, and neuronal cells. Cells are cultured in standard media and treated with the compound at various concentrations. JNK1/2 phosphorylation is assessed by Western blotting. NF-κB activation is assessed by measuring IκB degradation or NF-κB nuclear translocation. Anti-inflammatory activity is assessed by measuring cytokine production. Antioxidant activity is assessed by measuring ROS levels. Anticancer activity is assessed using cell viability and proliferation assays. Neuroprotective activity is assessed in neuronal cells exposed to neurotoxic insults. These cellular assays help validate the compound's multiple biological activities.
|
| Animal Protocol |
In vivo animal experiments with Isovitexin are conducted in models of inflammation, cancer, and neurodegenerative diseases. For anti-inflammatory studies, models of acute or chronic inflammation are used. For anticancer studies, tumor xenograft models are employed. For neuroprotective studies, models of Alzheimer's disease or other neurodegenerative disorders are used. Isovitexin is administered via oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints include inflammation reduction, tumor growth inhibition, and cognitive function improvement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Isovitexin have been partially characterized. As a flavonoid glycoside with a molecular weight of 432.38, it is expected to have moderate oral bioavailability. The compound's C-glucoside structure may affect its absorption and metabolism. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented. The compound should be stored as a powder at -20°C for up to three years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Isovitexin is not extensively characterized. As a natural flavonoid from various medicinal plants, it is generally considered to have a favorable safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Researchers should follow standard laboratory safety practices when handling Isovitexin.
|
| References |
|
| Additional Infomation |
Isohexurin is a C-glycoside compound composed of apigenin with a 1,5-dehydro-D-glucol substituent at the 6-position. It is an EC 3.2.1.20 (α-glucosidase) inhibitor and metabolite. It is a C-glycoside and a trihydroxyflavonoid. Its function is related to apigenin. It is the conjugate acid of isohexurin-7-ol salt. Isohexurin has been reported in tea (Camellia sinensis), soapberry (Gleditsia sinensis), and other organisms with relevant data. See also: acai berry (partial); fenugreek seeds (partial); monotypic hawthorn inflorescence (partial).
Isovitexin is a valuable research tool for studying JNK1/2 signaling, NF-κB activation, and inflammation. Its dual inhibition of JNK and NF-κB makes it useful for investigating the interplay between these pathways in inflammation and cancer. Its antioxidant and neuroprotective activities provide opportunities for studying oxidative stress and neurodegenerative diseases. As a flavonoid from various medicinal plants, it is also important for natural product chemistry and traditional medicine research. |
| Molecular Formula |
C21H20O10
|
|---|---|
| Molecular Weight |
432.3775
|
| Exact Mass |
432.105
|
| CAS # |
29702-25-8
|
| PubChem CID |
162350
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
807.0±65.0 °C at 760 mmHg
|
| Melting Point |
220-221ºC
|
| Flash Point |
287.1±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.743
|
| LogP |
1.28
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
690
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@@]([H])([C@]([H])([C@]1([H])C1C(=C([H])C2=C(C(C([H])=C(C3C([H])=C([H])C(=C([H])C=3[H])O[H])O2)=O)C=1O[H])O[H])O[H])O[H])O[H]
|
| InChi Key |
MYXNWGACZJSMBT-VJXVFPJBSA-N
|
| InChi Code |
InChI=1S/C21H20O10/c22-7-14-17(26)19(28)20(29)21(31-14)16-11(25)6-13-15(18(16)27)10(24)5-12(30-13)8-1-3-9(23)4-2-8/h1-6,14,17,19-23,25-29H,7H2/t14-,17-,19+,20-,21+/m1/s1
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
| Synonyms |
Saponaretin; Homovitexin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL | |
| 5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | |
| 10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
